Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
Désirée A M van OorschotManjit HunjanBenjamin BrackeStéphane LorencDesmond CurranHelen Starkie-CamejoPublished in: BMJ open (2019)
Under the model assumptions, RZV is predicted to avert more HZ and PHN cases compared with ZVL. Results were robust under different scenario and sensitivity analyses.